Ribonucleoside Diphosphate Adducts with Elliptinium Acetate, an Antitumor Agent
- 1 September 1987
- journal article
- research article
- Published by Taylor & Francis in Nucleosides and Nucleotides
- Vol. 6 (4) , 691-698
- https://doi.org/10.1080/15257778708073419
Abstract
The oxidized form of the antitumor agent elliptinium acetate is able to arylate adenosine and uridine 5′-diphosphate by attack of the 2′-0 position of the ribose and cyclisation, leading to spiro derivatives. Ring opening occurs under reducing conditions and leads to the formation of adducts at 2′ or 3′ positions. Spiro and uncyclised adducts showed low cytotoxicity against L1210 cells in vitro.Keywords
This publication has 7 references indexed in Scilit:
- Ribose as the preferential target for the oxidized form of elliptinium acetate in ribonucleos(T)ides. Biological activities of the resulting adductsJournal of Medicinal Chemistry, 1986
- Requirement for the presence of a 2′-α-OH group for the arylation of purine nucleosides by elliptinium acetate, an antitumour agentJournal of the Chemical Society, Chemical Communications, 1985
- Reinvestigation of the reaction of n-2-methyl-9-hydroxyellipticinium acetate with adenosine and methanol.Tetrahedron Letters, 1984
- Regioselective arylation of ribose in adenosine and guanosine with the antitumor drug N2-methyl-9-hydroxyellipticinium acetate.Proceedings of the National Academy of Sciences, 1984
- The ribonucleotide reductases — A unique group of metalloenzymes essential for cell proliferationPublished by Springer Nature ,1983
- Reduction of RibonucleotidesAnnual Review of Biochemistry, 1979
- Comparative cytotoxic and antitumoral effects of ellipticine derivatives on mouse L 1210 leukemiaChemico-Biological Interactions, 1979